This thesis is about the history of medications against rheumatoid arthritis and the new DMARDs currently under development. A major turning point in the history of pharmacological treatment against rheumatoid arthritis was the development and use of methotrexate.Unlike previous symptomatic drugs, methotrexate acts directly on the pathophysiology of rheumatoid arthritis, resulting in a significant improvement in the prognosis of many patients of rheumatoid arthritis. Further developments, such as targeted DMARDs containing Jak inhibitors and biological DMARDs such as IL-6 inhibitors and anti-TNFs, have enabled patients who could not achieve remission with methotrexate alone to achieve remission. In addition, new drugs targeting completely different steps of the pathomechanism from previously developed DMARDs are currently under development. While drugs for existing and new targets are being developed, another aspect of advance is the development of biosimilars which make treatments available at a lower cost. As a conclusion, many of new DMARDs are currently under development, and it is hoped that further advances of the developments will relieve more patients from suffering from rheumatoid arthritis in the future.